A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants (NCT02337751), a na phase 3 study. The primary outcome is Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE).

2. Clinical Question

In practical statistical terms, the question is descriptive: what safety events were recorded during exposure to TVP-1012 in this extension-study setting? The posted information also lists other safety outcomes, including laboratory, vital-sign, ECG, and body-weight events, as well as a change in an MDS-UPDRS score. Those listed outcomes do not replace the primary question, and their presence in the outcome list does not establish that numerical results or analyses were reported for them.

3. Trial Design

This is a Phase 3, multicenter, open-label, long-term extension study of TVP-1012 at 1 mg in early Parkinson's disease. The overall model is single group, allocation is listed as not applicable, and masking is listed as none. The study is marked completed. Its stated purpose is to evaluate long-term safety in Japanese participants with early Parkinson's disease.

The intervention description specifies TVP-1012 1 mg once daily, either before or after breakfast. The registry record lists enrollment as 198. That enrollment figure is not the same thing as the primary outcome's analysis population: the latter is described as a safety set that includes people who received at least one dose in this study and/or the preceding study. The safety-set description notes that it included 103 participants enrolled in this study and 14 who enrolled only in the preceding study. The registry record does not report a reconciliation between those figures and the enrollment figure.

The primary outcome is the number of participants with at least one treatment-emergent adverse event, assessed up to 52 weeks. Its description says data were collected from the first dose through the end of the study and that the timeframe covers both this study and the preceding study, each described as 26 weeks. The registry record lists safety groups with different exposure histories, but it explicitly cautions that this is not a randomized comparison and that the groups are not like-for-like controls. Consequently, the design supports a descriptive reading of the reported safety counts, not a causal comparison of treatment effects.

The registry record does not report the protocol's sample-size justification, interim-analysis plan, or a detailed statistical analysis plan. Those details should not be inferred from the Phase 3 label or from the posted outcome counts.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: All participants with Parkinson's disease who completed the 26-week treatment period in preceding study (TVP-1012/CCT-001: NCT02337725) were enrolled in this study. Participants in TVP-1012 group and in Placebo group in preceding study were assigned to TVP-1012+TVP-1012 Group and Placebo+TVP-1012 Group in this study, respectively.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety Analysis Set: All participants who received at least 1 dose of TVP-1012 during this study and/or the preceding study (TVP-1012/CCT-001: NCT02337725). The analysis set included 103 participants who enrolled in this study and 14 participants who enrolled only in TVP-1012/CCT-001 and received TVP-1012 (totally 117 participants).

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Safety Analysis Set; All participants who received at least one dose of TVP-1012 during this study and/or the preceding study (TVP-1012/CCT-001: NCT02337725). The analysis set included 103 participants who enrolled in this study and 14 participants who enrolled only in TVP-1012/CCT-001 and received TVP-1012 (totally 117 participants).

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE), measured over Up to 52 weeks.

The primary outcome counts participants who experienced at least one treatment-emergent adverse event (TEAE). It is a participant-level count: a participant is counted for the outcome if they experienced at least one qualifying event, rather than being counted repeatedly for each event. The registry record describes collection from the first dose of TVP-1012 through the end of the study, up to 52 weeks, and identifies the measure as a number of participants.

Safety studies commonly use an outcome of this kind to describe how many participants had an adverse event during a specified treatment-emergent observation period. It gives a broad summary of whether events occurred, while not by itself describing their severity, duration, cause, or clinical importance. Those aspects require separate information. A participant-level count also does not reveal whether one participant had one event or several.

The outcome is relevant to the stated long-term safety purpose, but the registry record does not report its numerical result. It therefore does not establish how many participants met the outcome, nor does it support a comparison of TEAE occurrence between groups. The record separately lists safety outcomes related to clinical laboratory tests, markedly abnormal vital signs, ECG findings, body weight, and an MDS-UPDRS score. Their listing alone does not provide their results or clarify how they were analyzed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record describes a participant count as its primary outcome and reports safety counts for two groups. The concepts below explain how such results are generally read; they do not imply that a particular inferential method was used in this study. The detailed statistical plan is not reported in the registry record.

What does a participant count represent?

A count of participants with at least one event answers how many people met an outcome definition during the stated observation period. It differs from a count of all events: a participant with multiple events may still contribute only once to a participant-level outcome. This summary is useful for describing how widely an outcome occurred among the people being observed. It does not describe the number of episodes, time until an event, event duration, or severity unless those are reported separately.

For interpretation, a count needs an appropriate denominator. The denominator indicates which participants were considered at risk or included in the analysis. Counts without denominators cannot show how common an event was in the group. Even with a denominator, the result describes the observed group; it does not by itself establish that treatment caused the event. The posted serious-event figures pair counts with at-risk group sizes, while the primary outcome result and its denominator are not reported in the registry record.

What do uncertainty estimates add?

In general, a confidence interval describes the range of values reasonably compatible with data under a specified statistical model and procedure. A narrow interval indicates greater statistical precision than a wide interval, while neither interval width nor inclusion of a particular value proves a causal effect. Confidence intervals for the primary outcome or a comparison are not reported in the registry record. No p-value for that outcome is reported either.

For a group comparison, statistical inference generally depends on a clear contrast, a suitable analysis population, and assumptions about how observations were collected. Random allocation can help make groups comparable on average, but this study's allocation is listed as not applicable, and the record warns that its two safety groups are not like-for-like controls. A numerical contrast between their counts would therefore not resolve the potential differences in treatment history or other characteristics. The registry record does not report an adjusted comparative analysis.

Why do study design and exposure matter?

In general, open-label means that masking is absent, as is also stated in this record. Knowledge of treatment can affect reporting, assessment, or decisions about follow-up, depending on the outcome and procedures. This is a general consideration, not evidence that such effects occurred in this study. The primary outcome is safety-related and covers a stated period up to 52 weeks, including the preceding study. The record does not report a time-to-event analysis or exposure-adjusted event rates, so the posted counts should be read as counts rather than as rates over person-time.

Over-dispersion is a general concern when event counts vary more than a simple statistical model expects. It can make uncertainty estimates from an overly restrictive model too small. It is most relevant to analyses of event counts, and it cannot be assessed from the participant-level counts alone. The registry record does not report a model for event-count dispersion or an analysis requiring such a model.

How should planning illustrations be read?

Sample-size planning asks how many participants a future study might need under stated assumptions to detect a chosen effect with a specified statistical procedure. It is not a measure of what the completed study observed, and it is not observed power. The planning assumptions described for this record use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the targeted effect is expressed as a fraction of the observed effect. These assumptions describe planning illustrations, not the trial's own design or an analysis of the posted safety counts.

Because the study is not a randomized, like-for-like two-arm comparison, illustrations based on a two-arm contrast should not be mistaken for a valid treatment comparison in this trial. The protocol's own sample-size justification is not reported in the registry record. The record also does not report the observed primary-outcome effect needed to assess such planning assumptions. Sample-size calculations cannot compensate for absent outcome results, missing analysis details, or limitations in comparability.

What can be concluded from the listed analyses?

The record lists 6 outcome measures and 0 analyses. A listed outcome tells readers what was intended to be assessed, but does not show that a numerical result or statistical test is available. Without reported analyses, readers cannot determine which comparisons, if any, were conducted, what adjustment methods were used, or how uncertainty was quantified. These are not details that can be inferred from the study's phase or from the descriptive safety counts.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Placebo + TVP-1012 Group", "TVP-1012 + TVP-1012 Group")
n      <- c(95, 117)
events <- c(51, 91)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Placebo + TVP-1012 Group  95  51  53.7  43.2  64.0  43.7  63.4  43.7  63.4
ARM  TVP-1012 + TVP-1012 Group  117  91  77.8  69.2  84.9  69.4  84.4  69.4  84.3

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists 6 outcome measures, including the primary TEAE count and secondary measures concerning clinical laboratory tests, vital signs, ECG findings, body weight, and MDS-UPDRS Part II + Part III total score. It lists 0 analyses. The numerical primary-outcome result is not reported in the registry record, and the record does not provide results or analysis details for the listed secondary outcomes in the information available for this account.

Multiplicity arises when several outcomes or statistical tests are considered. In general, testing many outcomes can increase the chance of at least one apparently notable result by chance if no adjustment or prespecified interpretation plan is used. A statistical analysis plan may explain which outcomes are confirmatory, how tests are ordered, or whether adjustment is applied. Such a plan and any multiplicity procedure are not reported in the registry record, so it is not possible to assess how multiple outcomes were handled.

Missing-data methods are also not reported in the registry record. It does not describe how missing outcome assessments, incomplete follow-up, or participants who discontinued were handled for the primary outcome. The outcome description gives a timeframe up to 52 weeks and defines a safety analysis set by receipt of at least one dose in this study and/or the preceding study. That definition does not, by itself, explain how incomplete observation was treated.

The record does not report a participant flow accounting for all enrollment and analysis populations, or a reconciliation of the enrollment figure with the safety-group denominators. It is therefore not possible to determine from the posted information why those populations differ or how missingness may affect interpretation. These limits matter because outcome counts and comparisons depend on who was observed and how the analysis population was defined.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: mechanical ileus (1.1%), osteoarthritis (1.1%), prostate cancer (1.1%), microscopic polyangiitis (1.1%), inguinal hernia (0.9%).

The serious-event figures are counts of affected participants in the named groups: 4 of 95 at risk in the Placebo + TVP-1012 Group, and 6 of 117 at risk in the TVP-1012 + TVP-1012 Group. The record reports 0 deaths in each group. For other events, the corresponding figures are 23 of 95 and 49 of 117. These are descriptive results, not evidence of a treatment effect.

The registry record cautions that the groups are not a like-for-like control comparison and that the study is not randomized. Their counts should therefore not be read as a head-to-head estimate of relative safety. The record does not report an adjusted comparison or uncertainty estimates for these figures. It also does not provide, in the posted information, the detail needed to understand whether participants could contribute to more than one event category.

Term-level serious-event entries include Mechanical ileus, Osteoarthritis, Prostate cancer, and Microscopic polyangiitis at 1.1% each, and Inguinal hernia and Leukoplakia oral at 0.9% each. The registry record does not report the denominator and other context for these percentages in the posted information. They should be interpreted as listed terms, not as a basis for comparing groups or estimating an individual participant's risk.

13. What the Result Does, and Does Not, Mean

The posted results establish that the registry record contains descriptive safety counts for two named groups and reports no deaths in either group. They also identify the primary safety outcome as the number of participants with at least one TEAE during an observation period up to 52 weeks. The primary outcome's numerical result is not reported in the registry record, so the central count cannot be stated from the posted information.

The counts in the safety groups do not establish that TVP-1012 caused or prevented an event. The groups are not randomized, and the registry record expressly warns that they are not like-for-like control groups. Their different labels and denominators do not create a valid causal contrast. No adjusted comparison, confidence interval, or p-value for the primary outcome is reported.

Nor do the listed counts describe every aspect of safety. A count of participants affected does not show how many events each participant had, how long events lasted, their severity, or whether they were judged related to treatment. The primary endpoint is framed as TEAEs, but its result is absent. Separate safety outcomes are listed, yet their numerical results and methods are not reported in the record.

These limits do not erase the descriptive value of the posted safety information: it records event counts in the stated groups and gives a defined observation timeframe for the primary outcome. But the information does not support a definitive comparative conclusion, a causal interpretation, or a complete account of long-term safety. The record also does not report enough about missing data, participant follow-up, or analysis methods to assess how those issues might affect the estimates.

Thus, the appropriate interpretation is narrow. The trial is a completed, open-label extension focused on safety; the registry record provides some event counts, but not the primary outcome result or the analysis detail needed for stronger statistical conclusions. Absence of a reported result is not evidence that no events occurred.

14. Why This Trial Matters Statistically

This study is statistically informative as an example of why design and reporting context matter as much as a count. The registry record identifies a completed Phase 3 extension with a long-term safety purpose, but it also states that allocation is not applicable and masking is absent. The two named safety groups are explicitly not like-for-like control groups. These design details limit what can be learned from comparing their observed counts.

The primary endpoint is a participant-level safety measure, and the record specifies its observation period and the broad definition of its analysis population. Clear definitions are valuable because an event count is only interpretable when readers know what was counted, over what period, and among whom. At the same time, the numerical result for that primary outcome is not reported in the registry record. This makes the distinction between an outcome being named and an outcome being reported especially important.

The safety figures also illustrate why counts should not be detached from their denominators or group context. The posted counts describe participants affected in the stated groups, while the study's nonrandomized design prevents a simple causal reading. A reader needs the design, analysis population, event definition, and uncertainty information together to judge the strength of a comparison. Several of those elements are absent or limited in the registry record.

Finally, the record lists several outcome measures but no analyses. This emphasizes that a trial's outcome inventory is not a substitute for results, statistical methods, or missing-data reporting. For researchers, clinicians, and statisticians, the case underscores the value of complete outcome reporting and cautious interpretation of descriptive safety data when there is no randomized control contrast.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for statistical interpretation is that the numerical result for the primary TEAE outcome is not reported in the registry record. Without that result and its analysis denominator, the stated primary safety question cannot be answered quantitatively from the record. The record also lists 0 analyses, so no formal inferential assessment of the outcome is available in the posted information.

The study is open-label and single-group in its overall model, with allocation listed as not applicable. Although the registry record gives safety counts for two groups with different labels, it explicitly states that they do not represent a randomized, like-for-like control comparison. The counts therefore cannot support a causal comparison. The record does not report an adjusted analysis to address differences between groups.

The primary outcome's safety analysis set includes participants who received at least one dose in this study and/or the preceding study. The description mentions participants enrolled in the extension and participants enrolled only in the preceding study. The registry record does not report a reconciliation between that population, the enrollment figure, and the denominators in the safety groups. It also does not report missing-data methods, the handling of incomplete follow-up, or a complete participant flow.

Other limitations include the absence of reported confidence intervals, p-values, and detailed statistical methods for the primary result. The registry record does not report multiplicity procedures for the listed outcome measures, nor the protocol's sample-size justification or interim-analysis plan. Term-level serious-event percentages are listed, but their denominator and additional context are not reported in the posted information. These gaps constrain interpretation of both the primary outcome and the secondary safety information.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants — NCT02337751.
• Registry record last updated 2022-03-02; status last verified 2022-02.
• Results first posted 2019-02-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This completed Phase 3 study is an open-label, long-term extension of TVP-1012 at 1 mg in early Parkinson's disease. The stated purpose is to evaluate long-term safety in Japanese participants. Treatment is described as once daily, either before or after breakfast. The registry record lists enrollment as 198.

The primary outcome is the number of participants experiencing at least one TEAE, assessed up to 52 weeks and described as covering this study and the preceding study. Its numerical result is not reported in the registry record. The record lists safety counts for a Placebo + TVP-1012 Group and a TVP-1012 + TVP-1012 Group, while cautioning that they are not a randomized, like-for-like comparison. It lists 6 outcome measures and 0 analyses. These details support a descriptive account of some safety findings, but not a causal group comparison or a complete statistical assessment.